Verona Pharma plc (VRNA)
Delisted
NASDAQ (NMS) NASDAQ (NMS) Primary Want to track VRNA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Verona (VRNA) Stock Surges 36% in the Past Month: Here's Why
Verona Pharma (VRNA) surges on the recent FDA approval for its lead drug, which is the first inhaled COPD product with a novel mechanism of action in more than 20 years.
Zacks | 1 year ago
First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product
On Wednesday, the FDA approved Verona Pharma plc's VRNA Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.
Benzinga | 1 year ago
Verona Pharma's inhaled COPD therapy to be priced at $2,950 per month
Verona Pharma's therapy for treating a chronic lung disease will be sold in the U.S. at a wholesale price of $2,950 per month, the U.K.-based company said on a conference call on Thursday.
Reuters | 1 year ago
US FDA approves Verona Pharma's therapy for 'smoker's lungs'
The U.S. Food and Drug Administration has granted approval for a treatment from Verona Pharma for a chronic lung disease that commonly affects smokers, the U.K.-based company said on Wednesday.
Reuters | 1 year ago
2025 © Marketlog. All Rights Reserved.
